Algert Global LLC purchased a new position in shares of HealthEquity, Inc. (NASDAQ:HQY – Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 8,679 shares of the company’s stock, valued at approximately $748,000.
A number of other large investors have also recently bought and sold shares of HQY. Rise Advisors LLC bought a new position in HealthEquity during the first quarter worth $28,000. International Assets Investment Management LLC acquired a new stake in shares of HealthEquity in the 2nd quarter valued at about $35,000. YHB Investment Advisors Inc. bought a new stake in HealthEquity in the 1st quarter valued at about $40,000. Fidelis Capital Partners LLC acquired a new position in HealthEquity during the 1st quarter worth approximately $42,000. Finally, Parallel Advisors LLC boosted its holdings in HealthEquity by 255.5% in the fourth quarter. Parallel Advisors LLC now owns 679 shares of the company’s stock worth $45,000 after acquiring an additional 488 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.
HealthEquity Price Performance
Shares of NASDAQ HQY opened at $83.09 on Friday. The company has a market capitalization of $7.23 billion, a PE ratio of 90.32, a PEG ratio of 1.25 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock’s 50 day moving average price is $76.47 and its 200-day moving average price is $79.17. HealthEquity, Inc. has a twelve month low of $61.81 and a twelve month high of $88.26.
Insiders Place Their Bets
In related news, Director Frank Corvino sold 1,247 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the transaction, the director now owns 4,823 shares in the company, valued at approximately $387,093.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the transaction, the insider now owns 89,769 shares in the company, valued at $7,168,952.34. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Frank Corvino sold 1,247 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total transaction of $100,084.22. Following the completion of the sale, the director now directly owns 4,823 shares in the company, valued at approximately $387,093.98. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,952 shares of company stock valued at $3,526,147. Company insiders own 2.20% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on HQY shares. Barrington Research restated an “outperform” rating and set a $105.00 price objective on shares of HealthEquity in a report on Friday, September 20th. Royal Bank of Canada restated an “outperform” rating and set a $92.00 price objective on shares of HealthEquity in a report on Wednesday, September 4th. Wells Fargo & Company raised their price objective on shares of HealthEquity from $107.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, June 20th. Bank of America decreased their target price on shares of HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $105.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $103.83.
Check Out Our Latest Research Report on HQY
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles
- Five stocks we like better than HealthEquity
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- Conference Calls and Individual Investors
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 9/30 – 10/4
Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY – Free Report).
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.